D3938
Anti-DR5 antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
Synonym(s):
Anti-Death Receptor 5, Anti-KILLER, Anti-TRAIL-R2, Anti-TRICK2
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 57 kDa
species reactivity
human
technique(s)
microarray: suitable
western blot: 2 μg/mL using human HeLa and K562 cell extracts
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... TNFRSF10B(8795)
General description
DR5 is a death domain-containing receptor that is activated through a p53-depedent pathway in response to radiation and DNA damage . DR5 is involved in caspase activation and cell apoptosis . Anti-DR5 antibody is specific for DR5 in humans.
Immunogen
synthetic peptide corresponding to amino acids 388-407 of the human DR5 precursor.
Application
Anti-DR5 antibody may be used in western blot (1 μg/mL using human HeLa and K562 cell extracts), immunoblot and microarray.
Physical form
Solution in phosphate buffered saline containing 0.02% sodium azide
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Oncogene, 19(14), 1735-1743 (2000-04-25)
KILLER/DR5, a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor gene, has been shown to be induced by DNA damaging agents and radiation in a p53-dependent manner. Although TRAIL is a potential therapeutic agent for cancer, the induction mechanism of
Oncogene, 18(47), 6411-6418 (1999-12-22)
The TRAIL death receptor KILLER/DR5 is induced by DNA damaging agents in wild-type p53-expressing cells. Here we show that, unlike the p53-target CDK-inhibitor p21WAF1/CIP1, the TRAIL death receptor KILLER/DR5 is only induced in cells undergoing p53-dependent apoptosis and not cell
Blood cells, molecules & diseases, 47(3), 182-197 (2011-07-22)
The number of erythroblasts generated ex-vivo under human-erythroid massive-amplification conditions by mononuclear cells from one unit of adult blood (~10(10)) are insufficient for transfusion (~10(12) red cells), emphasizing the need for studies to characterize cellular interactions during culture to increase
Molecular cancer research : MCR, 8(5), 729-738 (2010-05-06)
Bortezomib (VELCADE) could sensitize certain human renal cell carcinoma (RCC) lines to the apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Analysis of seven human RCC showed a clear increase in the sensitivity of four of the RCC to
Methods in molecular biology (Clifton, N.J.), 414, 221-239 (2008-01-08)
The extrinsic apoptosis pathway is activated when certain members of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) are oligomerized by their cognate ligands that are members of the TNF superfamily (TNFSF). The apoptosis-inducing capacity of a member of the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service